Meeting Program
EHA-SWG Secondary AML – April 2025
09:00 – 09:15 Opening & Welcome
09:15 – 10:00 Keynote: Classification and epidemiology of secondary and therapy-related leukemias
Chair: Maria Teresa Voso (Italy)
- Coleman Lindsley (United States)
10:00 – 10:30 Coffee break
10:30 – 11:45 Session 1: Susceptibility and mechanisms of secondary leukemogenesis
Chair: Shahram Kordasti (United Kingdom)
- BM-failure syndromes
Carmelo Gurnari (Italy) - DDX41 and other susceptibility genes
Marie Sebert (France) - TP53 and other classifier mutations
Andrew Wei (Australia) - Panel discussion
All speakers
11:45 – 13:00 Oral Abstracts Session 1
Chairs: Kirsten Grønbæk (Denmark) & Konstanze Döhner (Germany)
- NAVIGATING THE BORDERLAND OF SECONDARY ΑΜL: REFINING THE DIAGNOSTIC QUALIFIERS AND EVALUATING THE IMPACT OF 20% BLAST THRESHOLD
Enrico Attardi (Italy) - HIGHLY VARIABLE ALTERNATIVE SPLICING PROFILES IN SPLICEOSOME-MUTATED SECONDARY AML REVEALED BY LONG-READ SINGLE-CELL SEQUENCING
Jonas Berger (Germany) - COMPREHENSIVE MULTI-OMICS EXPLORATION OF MOUSE MODELS REFLECTING RECURRENT MUTATIONS OF HUMAN AML
Paul Jung (Germany) - CANCER GENE DISCOVERY IN ASXL1-MUTATED AML THROUGH SINGLE-CELL TRANSPOSON AND TRANSCRIPTOME SEQUENCING
Francis Baumgartner (Germany) - CARTOGRAPHY OF CLINICAL AND MOLECULAR FEATURES OF THERAPY-RELATED MYELOID NEOPLASMS: INSIGHTS FROM THE ITALIAN REGISTRY
Elisa Meddi (Italy) - SWING BETWEEN TWO LINEAGES. THE EXCEPTIONAL CASE OF PRIMARY MYELOFIBROSIS TRANSFORMATION TO ACUTE LYMPHOBLASTIC LEUKEMIA AND SUBSEQUENT RELAPSE OF ACUTE MYELOID LEUKEMIA
Magdalena Karasek (Poland)
13:00 – 14:00 Lunch break
Breakout Sessions
14:00 – 15:30 Breakout A: Drugs and diseases in th-related AML
Chair: Jordi Sierra (Spain)
- Solid tumors and PARPi
Elisabetta Todisco (Italy) - Hematologic malignancies (topo-II inhibitors, lenalidomide, autologous transplantation)
Sylvain Garciaz (France) - Secondary leukemias with recurrent genetic abnormalities
Coleman Lindsley (United States)
14:00 – 15:30 Breakout B: Exploring the multifactorial events of AML transformation
Chair: Paresh Vyas (United Kingdom)
- Quantitative dynamics for transformation of MDS to AML
Verena Korber (United Kingdom) - AML microenvironment
Dominique Bonnet (United Kingdom) - Modelling secondary AML using human iduced pluripotent stem cells
Eirini Papapetrou (United States)
15:30 – 15:45 Coffee break
15:45 – 17:00 Session 2: Mechanisms of clonal progression
Chair: Christoph Plass (Germany)
- CHIP and clinical management
Kirsten Grønbæk (Denmark) - Clonal trajectories from normal hemopoiesis to clonal hemopoiesis (CH and CCUS) to MDS and MPD and then to AML
Coleman Lindsley (United States) - Progressive immune remodeling as hemopoiesis changes over time from normal hemopoiesis to sAML
Shahram Kordasti (United Kingdom) - Panel discussion
All speakers
17:00 – 18:00 AbbVie Satellite Symposium: Therapeutic Strategies and Novel Insights in Secondary AML: Sharing Expert Knowledge
- Welcome and Introduction
Konstanze Döhner (Germany) - Therapeutic Strategies and Novel Insights in Secondary AML: Sharing Expert Knowledge
Franziska Modemann (Germany) - Targeting Complexity: The Role of Genetic Profiles in secondary AML
Lars Bullinger (Germany) - Panel Discussion
- Closing Remarks
Konstanze Döhner (Germany)
18:00 – 19:00 Welcome reception & poster walk
08:30 – 09:15 Keynote: Complex karyotype in sAML
Chair: Konstanze Döhner (Germany)
- Christoph Plass (Germany)
09:15 – 10:30 Session 3: Special situations
Chair: Carmelo Gurnari (Italy)
- sAML in childhood (including after gene-therapy)
Pietro Merli (Italy) - After CAR-T cell treatment
Michael Hudecek (Germany) - Donor-derived leukemias after HSCT
Daniel Wiseman (United Kingdom) - Panel discussion
10:30 – 10:45 Coffee break
10:45 – 12:00 Oral Abstract Session 2
Chair: Maria Teresa Voso (Italy) & Marie Sebert (France)
- PHYLOGENETICS OF MDS-TO-AML PROGRESSION AT SINGLE-CELL RESOLUTION: A GENETIC AND EPIGENETIC APPROACH TO UNRAVEL CLONES RESISTANT TO HYPOMETHYLATING AGENTS
Ignacio Campillo-Marcos (Spain) - HIGH RISK MUTATIONS IN CRITICAL GENES DO NOT SIGNIFICANTLY AFFECT REMISSION RATES AND MRD CLEARANCE IN AML PATIENTS RECEIVING CPX-351 INDUCTION
Paola Minetto (Italy) - EFFICACY OF CPX-351 IN SECONDARY ACUTE MYELOID LEUKEMIA DEFINED ACCORDING TO WHO 2022 CLASSIFICATION
Fabio Guolo (Italy) - COMPARING OUTCOMES BETWEEN CPX-351 AND FLUDARABINE-BASED INDUCTION IN SECONDARY ACUTE MYELOID LEUKEMIA IN THE REAL-WORLD SETTING: THE PROGNOSTIC ROLE OF MEASURABLE RESIDUAL DISEASE
Carola Riva (Italy) - ANALYSIS OF GERMLINE VARIANTS IN TAIWANESE PEDIATRIC AML PATIENTS: FOCUS ON SECONDARY AML AND FAMILY CANCER HISTORY
Der-Shiun Wang (Taiwan) - RETROSPECTIVE EVALUATION OF THERAPY-RELATED ACUTE MYELOID LEUKEMIAS: A SINGLE CENTER EXPERIENCE
Denis Cetin (Türkiye)
12:00 – 13:00 Session 4: Treatment
Chair: Andrew Wei (Australia)
- Conventional CHT
Christian Recher (France) - Semi-intensive treatment
Andrew Wei (Australia) - Transplant-related issues in sAML
Jorge Sierra (Spain) - Panel discussion
All speakers
13:00 – 13:15 Takeaways & Closing
13:15 – 14:00 Farewell lunch